Table 2.
INH-Resistance conferring mutations in 180 INH-R (85 %) and 32 INH-S (15 %) isolates
| Drug resistance | Genes | No. of isolates | Changes | |
|---|---|---|---|---|
| INHR | 180 | Nucleotides | Amino acid | |
| 3 | ∆ katG | |||
| Single mutation | ||||
| 1 | GTC/GGC | V284Ga | ||
| 1 | AGC/AAC | S315N | ||
| 1 | AGC/GGC | S315G | ||
| 78 | AGC/ACC | S315T | ||
| katG | 1 | CCG/CGG | P375Ra | |
| 1 | TAC/TGC | Y413Ca | ||
| 1 | del G1284 | frameshifta | ||
| 1 | TGG/TCG | W438S | ||
| 1 | GAC/AAC | D448Na | ||
| Multiple mutations | ||||
| 1 | AGC/ACC, TGA/TAA | S315T, 343Stop | ||
| 1 | AGC/ACC, GAT/CAT | S315T, D387Hb | ||
| 1 | AGC/ACC, GTC/GAC | S315T, V450Db | ||
| 1 | AGC/ACC, GGC/AGC | S315T, G451Sb | ||
| Single mutations | ||||
| inhA | 3 | TCG/GCG | S94A | |
| 1 | -8 T/C | None | ||
| inhA-p | 37 | -15C/T | None | |
| 3 | -17G/T | None | ||
| Multiple mutations | ||||
| inhA-p | 1 | -15C/T, -47 G/T | None | |
| inhA, inhA-p | 1 | GGA/GGC, -15C/T | G3G, None | |
| 2 | ATC/ACC, -15C/T | I21T, None | ||
| 3 | ATC/GTC, -15C/T | I21V, None | ||
| katG, inhA | 1 | AGC/ACC, GGA/GGC | S315T, G3G | |
| 3 | GAA/GAC, -15C/T | E261D, None | ||
| katG, inhA-p | 1 | CCG/TCG, -15C/T | P280Sb, None | |
| 1 | TCG/GCG, -15C/T | S303Ab, None | ||
| 1 | ACC/GCC, -15C/T | T314A, None | ||
| 1 | AGC/AAC, -47G/C | S315N, None | ||
| 2 | AGC/ACC, -8 T/A | S315T, None | ||
| 3 | AGC/ACC, -8 T/C | S315T, None | ||
| 2 | AGC/AAC, -15C/T | S315T, None | ||
| 1 | AGC/AAC, -102G/A | S315T, None | ||
| 1 | ACT/ATT, -15C/T | T308I, None | ||
| katG, inhA, inhA-p | 19 | WT | None | |
| INHS | katG, inhA, inhA-p | 32 | WT | None |
aUndescribed mutations that occur alone; bundescribed mutations that occur in combination with another resistance-associated mutation; inhA-p, inhA promoter, del, deletion; WT wild-type sequence, R resistant, S susceptible